Skye Bioscience to participate in investment and medical conferences.

Skye Bioscience, a clinical-stage biotech company, will participate in several upcoming investment and medical conferences, including the Cantor Global Healthcare Conference, H.C. Wainwright Global Investment Conference, Morgan Stanley Global Healthcare Conference, Obesity Science & Innovation, and European Association for the Study of Diabetes Annual Meeting. The company will present its obesity and metabolic health disorder therapeutic pipeline through fireside chats, presentations, and keynote panels.

Skye Bioscience, Inc. (Nasdaq: SKYE), a clinical-stage biotech company focused on unlocking new therapeutic pathways for obesity and metabolic health disorders, has announced its participation in several upcoming investment and medical conferences in September 2025. The company will present its obesity and metabolic health disorder therapeutic pipeline through fireside chats, presentations, and keynote panels.

Skye will participate in three major investment conferences: the Cantor Global Healthcare Conference (Sept. 5), the H.C. Wainwright Global Investment Conference (Sept. 8), and the Morgan Stanley Global Healthcare Conference (Sept. 10). Additionally, the company will attend two medical conferences: Obesity Science & Innovation in Boston and the European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna.

At the Cantor Global Healthcare Conference, Skye will participate in a fireside chat and one-on-one meetings. At the H.C. Wainwright Global Investment Conference, Skye will present and also engage in one-on-one meetings. At the Morgan Stanley Global Healthcare Conference, Skye will participate in a fireside chat and one-on-one meetings.

In the medical conferences, Skye will present data on nimacimab, a CB1 receptor antibody for the treatment of metabolic associated fatty liver disease (MAFLD). At Obesity Science & Innovation, Skye will participate in a keynote panel titled "Pipeline priorities - exploring leading and emerging targets shaping the future of obesity therapeutics." At the EASD Annual Meeting, Skye will present an oral presentation titled "A multiple dose study to evaluate the safety and tolerability of nimacimab, a peripherally restricted, inhibitory CB1 receptor antibody in subjects with metabolic associated fatty liver disease (MAFLD)."

Available webcasts for the presentations will be accessible on Skye’s website. The company is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®).

Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. The company aims to change weight loss standards of care and improve the safety and tolerability profile of its therapies.

The upcoming conferences provide an opportunity for Skye to engage with investors and medical professionals, showcase its therapeutic pipeline, and discuss its clinical trial results. The company's participation in these conferences is a significant step in its mission to unlock new therapeutic pathways for metabolic health disorders.

References:
[1] https://www.stocktitan.net/news/SKYE/skye-bioscience-to-participate-in-upcoming-investment-and-medical-ujxvza2853bs.html
[2] https://www.marketscreener.com/news/skye-bioscience-to-participate-in-upcoming-investment-and-medical-conferences-ce7c51d3df88fe23